1
|
Maeda Y, Wada H, Sugiyama D, Saito T, Irie T, Itahashi K, Minoura K, Suzuki S, Kojima T, Kakimi K, Nakajima J, Funakoshi T, Iida S, Oka M, Shimamura T, Doi T, Doki Y, Nakayama E, Ueda R, Nishikawa H. Depletion of central memory CD8 + T cells might impede the antitumor therapeutic effect of Mogamulizumab. Nat Commun 2021; 12:7280. [PMID: 34907192 PMCID: PMC8671535 DOI: 10.1038/s41467-021-27574-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2020] [Accepted: 11/29/2021] [Indexed: 11/09/2022] Open
Abstract
Regulatory T (Treg) cells are important negative regulators of immune homeostasis, but in cancers they tone down the anti-tumor immune response. They are distinguished by high expression levels of the chemokine receptor CCR4, hence their targeting by the anti-CCR4 monoclonal antibody mogamulizumab holds therapeutic promise. Here we show that despite a significant reduction in peripheral effector Treg cells, clinical responses are minimal in a cohort of patients with advanced CCR4-negative solid cancer in a phase Ib study (NCT01929486). Comprehensive immune-monitoring reveals that the abundance of CCR4-expressing central memory CD8+ T cells that are known to play roles in the antitumor immune response is reduced. In long survivors, characterised by lower CCR4 expression in their central memory CD8+ T cells possessed and/or NK cells with an exhausted phenotype, cell numbers are eventually maintained. Our study thus shows that mogamulizumab doses that are currently administered to patients in clinical studies may not differentiate between targeting effector Treg cells and central memory CD8+ T cells, and dosage refinement might be necessary to avoid depletion of effector components during immune therapy.
Collapse
MESH Headings
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized/therapeutic use
- Antineoplastic Agents/therapeutic use
- CD8-Positive T-Lymphocytes/drug effects
- CD8-Positive T-Lymphocytes/metabolism
- Dose-Response Relationship, Drug
- Female
- Humans
- Immunotherapy
- Killer Cells, Natural/drug effects
- Killer Cells, Natural/metabolism
- Male
- Memory T Cells/drug effects
- Middle Aged
- Neoplasms/drug therapy
- Neoplasms/immunology
- Receptors, CCR4/antagonists & inhibitors
- Receptors, CCR4/metabolism
- T-Lymphocytes, Regulatory/drug effects
- T-Lymphocytes, Regulatory/metabolism
- Treatment Outcome
Collapse
Grants
- Research Activity Start-up grant no. 15H06878, for Young Scientists (B) grant no. 17K15738 from the Ministry of Education, Culture, Sports, Science and Technology of Japan.the Projects for Cancer Research by Therapeutic Evolution [P-CREATE, no. 17cm0106322h0002]
- Scientific Research (B) grant no. 19H03729 from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
- the Development of Technology for Patient Stratification Biomarker Discovery grant [no.19ae0101074s0401] from the Japan Agency for Medical Research and Development (AMED)
- Grants-in-Aid for Scientific Research (S) grant no. 17H06162, for Challenging Exploratory Research grant no. 16K15551, from the Ministry of Education, Culture, Sports, Science and Technology of Japan; the Projects for Cancer Research by Therapeutic Evolution [P-CREATE, no. 16cm0106301h0001, the Development of Technology for Patient Stratification Biomarker Discovery grant [no.19ae0101074s0401] from the Japan Agency for Medical Research and Development (AMED), the National Cancer Center Research and Development Fund [no. 28-A-7 and 31-A-7]
Collapse
Affiliation(s)
- Yuka Maeda
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, 104-0045/Chiba, 277-8577, Japan
| | - Hisashi Wada
- Department of Clinical Research in Tumor Immunology, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan.
| | - Daisuke Sugiyama
- Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan
| | - Takuro Saito
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan
| | - Takuma Irie
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, 104-0045/Chiba, 277-8577, Japan
| | - Kota Itahashi
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, 104-0045/Chiba, 277-8577, Japan
| | - Kodai Minoura
- Department of Systems Biology, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan
| | - Susumu Suzuki
- Department of Tumor Immunology, Aichi Medical University, Aichi, 480-1195, Japan
| | - Takashi Kojima
- Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, 277-8577, Japan
| | - Kazuhiro Kakimi
- Department of Immunotherapeutics, The University of Tokyo Hospital, Tokyo, 113-8655, Japan
| | - Jun Nakajima
- Department of Thoracic Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-8655, Japan
| | - Takeru Funakoshi
- Department of Dermatology, Keio University School of Medicine, Tokyo, 160-8582, Japan
| | - Shinsuke Iida
- Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, 467-8601, Japan
| | - Mikio Oka
- Department of Respiratory Medicine, Kawasaki Medical School, Okayama 701-0192, Japan
| | - Teppei Shimamura
- Department of Systems Biology, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan
| | - Toshihiko Doi
- Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, 277-8577, Japan
| | - Yuichiro Doki
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan
| | - Eiichi Nakayama
- Faculty of Health and Welfare, Kawasaki University of Medical Welfare, Okayama, 701-0192, Japan
| | - Ryuzo Ueda
- Department of Tumor Immunology, Aichi Medical University, Aichi, 480-1195, Japan.
| | - Hiroyoshi Nishikawa
- Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, 104-0045/Chiba, 277-8577, Japan.
- Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.
| |
Collapse
|